BRIEF-Longeveron® Lomecel-B™ Data In Alzheimer’S Disease Selected For Late Breaking Poster Presentation At The Clinical Trials On Alzheimer’S Disease Conference

Reuters10-14

Oct 14 (Reuters) - Longeveron Inc :

* LONGEVERON® LOMECEL-B™ DATA IN ALZHEIMER’S DISEASE SELECTED FOR LATE BREAKING POSTER PRESENTATION AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD24)

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment